Department of Medicine, Division of Infectious Diseases, University of Connecticut Health Center, Farmington, Connecticut.
Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut.
J Am Acad Dermatol. 2014 Jul;71(1):1.e1-8; quiz 1.e8-9, 10. doi: 10.1016/j.jaad.2014.01.875.
Tumor necrosis factor-alfa levels are linked to disease severity in patients with inflammatory conditions, such as psoriasis. Inhibitors of this cytokine are commonly used with significant success in the treatment of such inflammatory disorders. Their use, however, can be plagued by infectious complications. An awareness of potential infections associated with these therapies is critical in order to maximize preventive efforts both before and during therapy. This review provides a guide for dermatologists caring for patients in need of this type of biologic therapy to preemptively address the infectious risks. Part I of this continuing medical education article reviews background information on the various infectious risks associated with tumor necrosis factor inhibitor therapy and appropriate historical data to obtain in the context of pretherapy evaluations.
肿瘤坏死因子-α水平与炎症性疾病（如银屑病）患者的疾病严重程度有关。这种细胞因子的抑制剂在治疗此类炎症性疾病方面取得了显著成功。然而，它们的使用可能会受到感染并发症的困扰。为了在治疗前后最大限度地提高预防效果，了解与这些治疗相关的潜在感染至关重要。本综述为需要这种生物治疗的患者提供了皮肤科医生护理指南，以预先解决感染风险。这篇继续教育文章的第一部分回顾了与肿瘤坏死因子抑制剂治疗相关的各种感染风险的背景信息，以及在治疗前评估中获取的适当历史数据。
